BJTJ-0003 is under clinical development by Beijing Tuojie Biomedical Technology and currently in Phase II for Thrombosis. According to GlobalData, Phase II drugs for Thrombosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BJTJ-0003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BJTJ-0003 overview
BJTJ-0003 is under development for the treatment of thrombosis. The drug candidate is a bio-fermented monoclonal antibody. It is administered through subcutaneous route.
Beijing Tuojie Biomedical Technology overview
Beijing Tuojie Biomedical Technology is a biotechnology company that specializes in the research and development of therapeutic proteins, peptide biopharmaceuticals and stem cell drugs for chronic diseases such as metabolic diseases, cardiovascular diseases, nervous system diseases and osteoarthritis. The company is headquartered in Beijing, China.
For a complete picture of BJTJ-0003’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
